Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation

Inclusion Criteria: * Diagnosis of: * Acute myeloid or lymphoid leukemia in remission, * Myelodysplastic syndrome, * Chronic lymphoid leukemia, * Non-Hodgkin lymphoma, * Hodgkin lymphoma, * Chronic myeloid leukemia in chronic or accelerated phase, * Myeloproliferative disorder, or * Multiple myeloma * Undergoing allogeneic HSC transplantation from a related or unrelated donor matched at least at 7 of 8 of the HLA-A, -B, -C, and DR loci ("8/8" or "7/8" match) * Undergoing allogeneic HSC transplantation after a myeloablative TBI-, busulfan-, or (non-myeloablative) melphalan-based pre-transplant conditioning regimen. Regimens for transplantation will include at one of the following agents, given in conjunction with fludarabine or cyclophosphamide: * Busulfan 130 mg/m2 iv daily x 2 (reduced intensity) or 4 days * TBI 150 cGy bid x8 doses (1200 Gy) * Melphalan 140 mg/m2. (Although melphalan is not a myeloablative regimen, it results in clinically significant mucositis and patients receiving this medication will be of considerable interest in the analysis of these data.) * Male or female patient age 18 years or older * Karnofsky performance status \> 70% at time of initiation of pre-transplant conditioning * Transplantation-specific co-morbidity score of \<5 at time of initiation of pre-transplant conditioning * Patients taking antihypertensive medications (including telmisartan) are eligible but the patient must discontinue treatment at least 48 hours prio…